Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
  1. Predictions
buy

Clinuvel Pharmaceuticals buy MinusSinus

Clinuvel Pharmaceuticals
Start price
€5.99
11.09.25 / 60%
Target price
€9.00
31.12.25
Performance (%)
14.19%
Price
€6.84
12.12.25
Summary
This prediction is currently active. The BUY prediction by MinusSinus currently has a performance of 14.19%. This prediction currently runs until 31.12.25. The prediction end date can be changed by MinusSinus at any time. MinusSinus has 60% into this prediction
Performance without dividends (%)
Name 1w 1m
Clinuvel Pharmaceuticals 0.073% 0.073%
iShares Core DAX® 0.734% -0.964%
iShares Nasdaq 100 -2.686% -2.409%
iShares Nikkei 225® -2.261% -4.038%
iShares S&P 500 -1.346% -1.510%

According to MinusSinus what are the pros and cons of Clinuvel Pharmaceuticals for the foreseeable future?

Pros
Could be very worthwhile Investment >20% year
Rising EBIT margin expected
positive Cash Flow expected
High Investments for future growth
Very valuable balance sheet
ROE higher than 15% per year
Small challenges to pay loans and raise capital
Capable Management
Good culture
Leading role in innovation
Strong uniques
Growths faster than the competition
Stable Large shareholder and/or long term investor
Market Leader or Top 3
Very small cyclical dependencies
Very Future proof/growth oriented business model
Revenue growth >5% per year expected
EBIT growth > 30% per year expected
Top Rating
Differentiated customer and product portfolio
Cons
Very low/no dividend yield expected
Higher risks for its business
Little known brand

Comments by MinusSinus for this prediction

In the thread Clinuvel Pharmaceuticals diskutieren
Prediction Buy
Perf. (%) 14.19%
Target price 9.000
Change
Ends at 31.12.25

Clinuvel aktuell mit cash-bereinigtem Kurs-Gewinn-Verhältnis von 8.6 bei Wachstum von 10% im Kerngeschäft und Wahrscheinlichkeit von >70%, mit Vitiligo in den nächsten Jahren einen Markt von 750 Millionen AUD zu erschließen. Das geplante Update des NASDAQ Listings auf Level 2 vor Ende diesen Jahres sollte als Katalysator für eine angemessene Bewertung dienen.

MinusSinus 
0
Report Share
11.09.25

Stopped prediction by MinusSinus for Clinuvel Pharmaceuticals

buy
Clinuvel Pharmaceuticals

Start price
Target price
Perf. (%)
€6.90
27.03.25
€25.00
27.04.25
-11.09%
28.04.25

Could be very worthwhile Investment >20% year
Rising EBIT margin expected
positive Cash Flow expected
Very low/no dividend yield expected
MinusSinus 
27.03.25 100%